Evidence map›Paper›PMID 30963936›Full record

ArticleProceedings. Biological sciences2019

Relevance of heterokaryosis for adaptation and azole-resistance development in Aspergillus fumigatus.

Jianhua Zhang, Eveline E Snelders, Bas J Zwaan, Sijmen E Schoustra, Ed J Kuijper, Maiken C Arendrup, Willem J G Melchers, Paul E Verweij, Alfons J M Debets

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings. Biological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Temperature duringbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. The Gβ-like ProteinJournal of fungi (Basel, Switzerland) · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Fungal spores are future-proofed.Nature microbiology · 2021
    Article
  11. Azole-Resistance Development; How theJournal of fungi (Basel, Switzerland) · 2021
    Review
  12. Article
  13. Article
  14. Parasexual recombination enablesERJ open research · 2020
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jianhua Zhang1 Laboratory of Genetics, Wageningen University , Droevendaalsesteeg 1, 6708 PB Wageningen , The Netherlands.
Eveline E Snelders1 Laboratory of Genetics, Wageningen University , Droevendaalsesteeg 1, 6708 PB Wageningen , The Netherlands.
Bas J Zwaan1 Laboratory of Genetics, Wageningen University , Droevendaalsesteeg 1, 6708 PB Wageningen , The Netherlands.
Sijmen E Schoustra1 Laboratory of Genetics, Wageningen University , Droevendaalsesteeg 1, 6708 PB Wageningen , The Netherlands.
Ed J Kuijper2 Department of Medical Microbiology, Leiden University Medical Center , Leiden , The Netherlands.
Maiken C Arendrup3 Unit of Mycology, Statens Serum Institut , Copenhagen , Denmark.
Willem J G Melchers6 Department of Medical Microbiology and Centre of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Centre , 6500 HB Nijmegen , The Netherlands.
Paul E Verweij6 Department of Medical Microbiology and Centre of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Centre , 6500 HB Nijmegen , The Netherlands.
Alfons J M Debets1 Laboratory of Genetics, Wageningen University , Droevendaalsesteeg 1, 6708 PB Wageningen , The Netherlands.
Wageningen University & Research · NLRadboud University Nijmegen · NLLeiden University Medical Center · NLStatens Serum Institut · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspergillus fumigatus causes a range of diseases in humans, some of which are characterized by fungal persistence. Aspergillus fumigatus, being a generalist saprotroph, may initially establish lung colonization due to its physiological versatility and subsequently adapt through genetic changes to the human lung environment and antifungal treatments. Human lung-adapted genotypes can arise by spontaneous mutation and/or recombination and subsequent selection of the fittest genotypes. Sexual and asexual spores are considered crucial contributors to the genetic diversity and adaptive potential of aspergilli by recombination and mutation supply, respectively. However, in certain Aspergillus diseases, such as cystic fibrosis and chronic pulmonary aspergillosis, A. fumigatus may not sporulate but persist as a network of fungal mycelium. During azole therapy, such mycelia may develop patient-acquired resistance and become heterokaryotic by mutations in one of the nuclei. We investigated the relevance of heterokaryosis for azole-resistance development in A. fumigatus. We found evidence for heterokaryosis of A. fumigatus in patients with chronic Aspergillus diseases. Mycelium from patient-tissue biopsies segregated different homokaryons, from which heterokaryons could be reconstructed. Whereas all variant homokaryons recovered from the same patient were capable of forming a heterokaryon, those from different patients were heterokaryon-incompatible. We furthermore compared heterokaryons and heterozygous diploids constructed from environmental isolates with different levels of azole resistance. When exposed to azole, the heterokaryons revealed remarkable shifts in their nuclear ratio, and the resistance level of heterokaryons exceeded that of the corresponding heterozygous diploids.

Indexed as

Genetic VariationAdaptation, BiologicalAntifungal AgentsAspergillus fumigatusAzolesDrug Resistance, FungalAntifungal AgentsAzolesAspergillus fumigatusazole resistancediploidflexible nuclear ratioheterokaryon incompatibility

Identifiers

PMID30963936
PMCPMC6408600
OpenAlexW2911963140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.